Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We d...
Saved in:
Published in | bioRxiv |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article Paper |
Language | English |
Published |
Cold Spring Harbor Laboratory
08.06.2024
|
Edition | 1.1 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides. |
---|---|
AbstractList | Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides.Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides. Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection. Electroencephalography (EEG) and electromyography (EMG) in awake mice demonstrated seizures. Using ion chromatography, we show that siRNAs can tightly bind Ca2+ and Mg2+ up to molar equivalents of the phosphodiester (PO)/phosphorothioate (PS) bonds independently of the structure or phosphorothioate content. Optimization of the formulation by adding high concentrations (above biological levels) of divalent cations (Ca2+ alone, Mg2+ alone, or Ca2+ and Mg2+) prevents seizures with no impact on the distribution or efficacy of the oligonucleotide. The data here establishes the importance of adding Ca2+ and Mg2+ to the formulation for the safety of CNS administration of therapeutic oligonucleotides. |
Author | Echeveria, Dimas Barker, Alexandra Paquette, Joseph Bramato, Brianna Yamada, Nozomi Anaclet, Christelle McHugh, Nicholas Sapp, Ellen Miller, Rachael Watts, Jonathan Khvorova, Anastasia Yamada, Ken Aronin, Neil Alterman, Julia DiFiglia, Marian |
Author_xml | – sequence: 1 givenname: Rachael surname: Miller fullname: Miller, Rachael – sequence: 2 givenname: Joseph surname: Paquette fullname: Paquette, Joseph – sequence: 3 givenname: Alexandra surname: Barker fullname: Barker, Alexandra – sequence: 4 givenname: Ellen surname: Sapp fullname: Sapp, Ellen – sequence: 5 givenname: Nicholas surname: McHugh fullname: McHugh, Nicholas – sequence: 6 givenname: Brianna surname: Bramato fullname: Bramato, Brianna – sequence: 7 givenname: Nozomi surname: Yamada fullname: Yamada, Nozomi – sequence: 8 givenname: Julia surname: Alterman fullname: Alterman, Julia – sequence: 9 givenname: Dimas surname: Echeveria fullname: Echeveria, Dimas – sequence: 10 givenname: Ken surname: Yamada fullname: Yamada, Ken – sequence: 11 givenname: Jonathan surname: Watts fullname: Watts, Jonathan – sequence: 12 givenname: Christelle surname: Anaclet fullname: Anaclet, Christelle – sequence: 13 givenname: Marian surname: DiFiglia fullname: DiFiglia, Marian – sequence: 14 givenname: Anastasia surname: Khvorova fullname: Khvorova, Anastasia – sequence: 15 givenname: Neil surname: Aronin fullname: Aronin, Neil |
BookMark | eNpNkEtLAzEUhYNUsNb-AHdZCjI1j5mkWUrxBfUB6nrIJHfayDSpmUxt_70dKygcuGfxnbv4TtHABw8InVMyoZTQK0ZYPiGiT6Gk4OoIDZlQLJsyUgz-9RM0btsPQghTgnKZD9H2JcIGfHJ-gbXpEmAPXQwpbJ1xaYdDjWdPrzgtIeo1dMkZHBq3CL4zDYTkLLT4y6VlT2BtrUsu-J-VZpdYe4sfF_vi_A9Qh7jqGt0zZ-i41k0L4987Qu-3N2-z-2z-fPcwu55nFRWFyqAoaG4Uq1ieSwJQF7aqKa9UzbkBaqSlhlQVlZJUBCwtFFdWai0EB6v30AhdHP5WLsSt25Tr6FY67speWklEn4O0P3Qdw2cHbSpXrjXQNNpD6NqSE0mme3WM8G90bXD9 |
Cites_doi | 10.1016/j.omtn.2019.11.020 10.1089/nat.2023.0068 10.1093/nar/gku142 10.1093/nar/gkab1126 10.1021/mp200250f 10.1089/nat.2021.0071 10.1038/s41467-022-33061-x 10.1038/ncomms9744 10.1113/jphysiol.1958.sp006022 10.1016/j.jhep.2023.06.013 10.1093/nar/gkaa595 10.1172/jci99081 10.1038/mtna.2016.50 10.1085/jgp.82.6.785 10.1016/0896-6273(95)90346-1 10.1172/jci.insight.152203 10.1002/cmdc.201000156 10.1093/nar/gkad067 10.1111/j.1471-4159.1986.tb13082.x 10.3233/jhd-229003 10.1089/108729003321629638 10.1056/NEJMoa1900907 10.1038/nn.3789 10.1056/NEJMc2300400 10.1038/s41587-022-01334-x 10.1261/rna.060079.116 10.1016/j.omtn.2022.12.010 10.1016/j.ymthe.2023.05.006 10.1093/nar/gkz771 10.1093/hmg/ddg169 10.1093/nar/gkaa299 10.1101/2021.02.14.431096 10.1021/bi982201 10.1093/nar/gky060 10.1146/annurev.pharmtox.010909.105654 10.1006/jmbi.1997.1383 10.1101/2023.05.26.542506 10.1038/nbt.3765 10.1016/j.neuron.2022.01.006 10.1016/j.omtn.2017.07.003 10.1089/nat.2023.0027 10.1126/science.aba4624 10.1038/d41573-023-00001-3 10.1016/j.bpj.2019.08.007 10.1523/jneurosci.2955-17.2018 10.1093/nar/gkg147 10.1038/npp.2017.152 10.1038/nrdp.2015.5 10.1038/s41587-019-0205-0 10.3233/jhd-239001 10.1038/s41573-021-00162-z 10.1056/NEJMoa1702752 10.1016/0143-4160(83)90047-7 10.1089/nat.2014.0506 10.1056/NEJMoa2204705 10.1113/jphysiol.1957.sp005808 10.1146/annurev-biochem-060409-092720 10.1038/s41573-024-00912-9 10.1261/rna.5205404 10.1016/j.neuron.2016.02.003 10.3389/fnins.2019.00755 10.1089/nat.2020.0923 10.1016/j.ymthe.2018.03.019 10.1016/j.celrep.2018.07.106 10.1177/1759091415578050 10.1002/mds.26020 10.3390/jcm9062004 |
ContentType | Journal Article Paper |
Copyright | 2024, Posted by Cold Spring Harbor Laboratory |
Copyright_xml | – notice: 2024, Posted by Cold Spring Harbor Laboratory |
DBID | 7X8 FX. |
DOI | 10.1101/2024.06.06.597639 |
DatabaseName | MEDLINE - Academic bioRxiv |
DatabaseTitle | MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: FX. name: bioRxiv url: https://www.biorxiv.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2692-8205 |
Edition | 1.1 |
ExternalDocumentID | 2024.06.06.597639v1 |
GroupedDBID | 7X8 8FE 8FH AFKRA ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI CCPQU HCIFZ LK8 M7P NQS PHGZM PHGZT PIMPY PROAC RHI FX. |
ID | FETCH-LOGICAL-b1659-e5514c92b24470eef5dbf13b9f33ce1c7d1c0bb1770b0ed15939d7aa663edaf33 |
IEDL.DBID | FX. |
ISSN | 2692-8205 |
IngestDate | Tue Jan 07 18:58:16 EST 2025 Fri Jul 11 07:25:29 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
License | This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1659-e5514c92b24470eef5dbf13b9f33ce1c7d1c0bb1770b0ed15939d7aa663edaf33 |
Notes | ObjectType-Working Paper/Pre-Print-3 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interest Statement: AK and NA are co-founders, on the scientific advisory board, and hold equities of Atalanta Therapeutics; AK is a founder of Comanche Pharmaceuticals and on the scientific advisory board of Aldena Therapeutics, AlltRNA, Prime Medicine, and EVOX Therapeutics; NA is on the scientific advisory board of Huntington's Disease Society of America (HDSA); Select authors hold patents or patent applications relating to the divalent siRNA and the methods described in this report. |
ORCID | 0000-0001-6966-7696 0000-0002-6195-0857 0000-0002-4594-0640 0000-0002-0526-8132 0000-0002-5714-8298 0000-0001-6928-8071 0000-0001-5706-1734 |
OpenAccessLink | https://www.biorxiv.org/content/10.1101/2024.06.06.597639 |
PQID | 3070802920 |
PQPubID | 23479 |
PageCount | 50 |
ParticipantIDs | biorxiv_primary_2024_06_06_597639 proquest_miscellaneous_3070802920 |
PublicationCentury | 2000 |
PublicationDate | 20240608 |
PublicationDateYYYYMMDD | 2024-06-08 |
PublicationDate_xml | – month: 06 year: 2024 text: 20240608 day: 08 |
PublicationDecade | 2020 |
PublicationTitle | bioRxiv |
PublicationYear | 2024 |
Publisher | Cold Spring Harbor Laboratory |
Publisher_xml | – name: Cold Spring Harbor Laboratory |
References | Finkel (2024.06.06.597639v1.3) 2017; 377 Mullard (2024.06.06.597639v1.7) 2023; 22 Tabrizi (2024.06.06.597639v1.28) 2019; 380 Harborth (2024.06.06.597639v1.46) 2003; 13 van Roon-Mom, Ferguson, Aartsma-Rus (2024.06.06.597639v1.4) 2023; 33 Crooke, Baker, Crooke, Liang (2024.06.06.597639v1.66) 2021; 20 Dhuri (2024.06.06.597639v1.8) 2020; 9 Frankenhaeuser, Meves (2024.06.06.597639v1.57) 1958; 142 Jia (2024.06.06.597639v1.15) 2023; 31 Anaclet (2024.06.06.597639v1.39) 2015; 6 Yamada (2024.06.06.597639v1.53) 2021; 49 Khvorova, Watts (2024.06.06.597639v1.52) 2017; 35 Leavitt, Tabrizi (2024.06.06.597639v1.32) 2020; 367 Hagedorn (2024.06.06.597639v1.16) 2022; 32 Alterman (2024.06.06.597639v1.12) 2019; 37 Gu (2024.06.06.597639v1.68) 2022; 110 Kamola (2024.06.06.597639v1.47) 2017; 8 Ferguson (2024.06.06.597639v1.13) 2021; 6 Bukhman, Draper (2024.06.06.597639v1.24) 1997; 273 Bates (2024.06.06.597639v1.29) 2015; 1 Durham (2024.06.06.597639v1.60) 1983; 4 Bennett, Swayze (2024.06.06.597639v1.9) 2010; 50 Nikan (2024.06.06.597639v1.27) 2016; 5 Crooke, Vickers, Liang (2024.06.06.597639v1.62) 2020; 48 Moazami (2024.06.06.597639v1.19) 2021 Slow (2024.06.06.597639v1.67) 2003; 12 Keith, Franklin (2024.06.06.597639v1.70) 2008 Aronin, DiFiglia (2024.06.06.597639v1.31) 2014; 29 Papaioannou, Fox (2024.06.06.597639v1.33) 1993; 43 Egli, Manoharan (2024.06.06.597639v1.1) 2023; 51 Conroy (2024.06.06.597639v1.35) 2022; 13 Han, Trinidad, Shi (2024.06.06.597639v1.59) 2015; 7 Brown (2024.06.06.597639v1.11) 2022; 40 Didiot (2024.06.06.597639v1.43) 2018; 24 Cunha, Bussi (2024.06.06.597639v1.51) 2017; 23 McColgan (2024.06.06.597639v1.6) 2023; 389 O’Reilly (2024.06.06.597639v1.61) 2023; 31 Miller (2024.06.06.597639v1.5) 2022; 387 Vickers, Rahdar, Prakash, Crooke (2024.06.06.597639v1.63) 2019; 47 Biscans (2024.06.06.597639v1.25) 2018; 26 Biscans (2024.06.06.597639v1.26) 2020; 48 Saudou, Humbert (2024.06.06.597639v1.30) 2016; 89 Murphy, Smith, Rapoport (2024.06.06.597639v1.41) 1986; 47 Kuter (2024.06.06.597639v1.2) 2023; 79 Erickson, Ferrari, Gompf, Anaclet (2024.06.06.597639v1.40) 2019; 13 Lipfert, Doniach, Das, Herschlag (2024.06.06.597639v1.20) 2014; 83 Aronin (2024.06.06.597639v1.18) 2022; 11 Anaclet (2024.06.06.597639v1.37) 2014; 17 Gebala, Herschlag (2024.06.06.597639v1.21) 2019; 117 Eckstein (2024.06.06.597639v1.44) 2014; 24 Liang (2024.06.06.597639v1.65) 2021; 31 Shen (2024.06.06.597639v1.50) 2018; 46 Estevez-Fraga, Tabrizi, Wild (2024.06.06.597639v1.17) 2023; 12 Frankenhaeuser, Hodgkin (2024.06.06.597639v1.56) 1957; 137 Tang, Khvorova (2024.06.06.597639v1.55) 2024; 23 Paxinos, Franklin (2024.06.06.597639v1.69) 2001; 2 Burdick (2024.06.06.597639v1.48) 2014; 42 Yamada (2024.06.06.597639v1.34) 2023 DiFiglia (2024.06.06.597639v1.71) 1995; 14 McFail-Isom, Shui, Williams (2024.06.06.597639v1.23) 1998; 37 Kubo (2024.06.06.597639v1.10) 2011; 8 Anaclet, Griffith, Fuller (2024.06.06.597639v1.38) 2018; 43 Aupy (2024.06.06.597639v1.64) 2020; 19 Draper (2024.06.06.597639v1.22) 2004; 10 Winkler, Stessl, Amartey, Noe (2024.06.06.597639v1.49) 2010; 5 Hahin, Campbell (2024.06.06.597639v1.58) 1983; 82 McCampbell (2024.06.06.597639v1.14) 2018; 128 Anaclet (2024.06.06.597639v1.36) 2018; 38 Harris, Sonnenblick (2024.06.06.597639v1.42) 1955; 27 Amarzguioui, Holen, Babaie, Prydz (2024.06.06.597639v1.45) 2003; 31 Belgrad, Fakih, Khvorova (2024.06.06.597639v1.54) 2024 |
References_xml | – volume: 19 start-page: 371 year: 2020 end-page: 383 ident: 2024.06.06.597639v1.64 article-title: Identifying and Avoiding tcDNA-ASO Sequence-Specific Toxicity for the Development of DMD Exon 51 Skipping Therapy publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2019.11.020 – year: 2024 ident: 2024.06.06.597639v1.54 article-title: Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation publication-title: Nucleic Acid Ther doi: 10.1089/nat.2023.0068 – volume: 42 start-page: 4882 year: 2014 end-page: 4891 ident: 2024.06.06.597639v1.48 article-title: Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides publication-title: Nucleic Acids Res doi: 10.1093/nar/gku142 – volume: 49 start-page: 12069 year: 2021 end-page: 12088 ident: 2024.06.06.597639v1.53 article-title: Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity publication-title: Nucleic Acids Res doi: 10.1093/nar/gkab1126 – volume: 8 start-page: 2193 year: 2011 end-page: 2203 ident: 2024.06.06.597639v1.10 article-title: Palmitic acid-conjugated 21-nucleotide siRNA enhances gene-silencing activity publication-title: Mol Pharm doi: 10.1021/mp200250f – volume: 32 start-page: 151 year: 2022 end-page: 162 ident: 2024.06.06.597639v1.16 article-title: Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features publication-title: Nucleic Acid Ther doi: 10.1089/nat.2021.0071 – volume: 13 start-page: 5802 year: 2022 ident: 2024.06.06.597639v1.35 article-title: Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models publication-title: Nat Commun doi: 10.1038/s41467-022-33061-x – volume: 6 start-page: 8744 year: 2015 ident: 2024.06.06.597639v1.39 article-title: Basal forebrain control of wakefulness and cortical rhythms publication-title: Nat Commun doi: 10.1038/ncomms9744 – volume: 142 start-page: 360 year: 1958 end-page: 365 ident: 2024.06.06.597639v1.57 article-title: The effect of magnesium and calcium on the frog myelinated nerve fibre publication-title: J Physiol doi: 10.1113/jphysiol.1958.sp006022 – volume: 79 start-page: 1150 year: 2023 end-page: 1158 ident: 2024.06.06.597639v1.2 article-title: Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial publication-title: J Hepatol doi: 10.1016/j.jhep.2023.06.013 – volume: 48 start-page: 7665 year: 2020 end-page: 7680 ident: 2024.06.06.597639v1.26 article-title: The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa595 – volume: 128 start-page: 3558 year: 2018 end-page: 3567 ident: 2024.06.06.597639v1.14 article-title: Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models publication-title: J Clin Invest doi: 10.1172/jci99081 – volume: 5 start-page: e344 year: 2016 ident: 2024.06.06.597639v1.27 article-title: Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain publication-title: Mol Ther Nucleic Acids doi: 10.1038/mtna.2016.50 – volume: 82 start-page: 785 year: 1983 end-page: 805 ident: 2024.06.06.597639v1.58 article-title: Simple shifts in the voltage dependence of sodium channel gating caused by divalent cations publication-title: J Gen Physiol doi: 10.1085/jgp.82.6.785 – volume: 14 start-page: 1075 year: 1995 end-page: 1081 ident: 2024.06.06.597639v1.71 article-title: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons publication-title: Neuron doi: 10.1016/0896-6273(95)90346-1 – volume: 6 year: 2021 ident: 2024.06.06.597639v1.13 article-title: Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep publication-title: JCI Insight doi: 10.1172/jci.insight.152203 – volume: 5 start-page: 1344 year: 2010 end-page: 1352 ident: 2024.06.06.597639v1.49 article-title: Off-target effects related to the phosphorothioate modification of nucleic acids publication-title: ChemMedChem doi: 10.1002/cmdc.201000156 – volume: 51 start-page: 2529 year: 2023 end-page: 2573 ident: 2024.06.06.597639v1.1 article-title: Chemistry, structure and function of approved oligonucleotide therapeutics publication-title: Nucleic Acids Res doi: 10.1093/nar/gkad067 – volume: 47 start-page: 1735 year: 1986 end-page: 1741 ident: 2024.06.06.597639v1.41 article-title: Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia publication-title: J Neurochem doi: 10.1111/j.1471-4159.1986.tb13082.x – volume: 11 start-page: 119 year: 2022 end-page: 120 ident: 2024.06.06.597639v1.18 article-title: Perspective: Tominersen Testing Finds a Way Forward publication-title: J Huntingtons Dis doi: 10.3233/jhd-229003 – volume: 13 start-page: 83 year: 2003 end-page: 105 ident: 2024.06.06.597639v1.46 article-title: Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing publication-title: Antisense Nucleic Acid Drug Dev doi: 10.1089/108729003321629638 – volume: 380 start-page: 2307 year: 2019 end-page: 2316 ident: 2024.06.06.597639v1.28 article-title: Targeting Huntingtin Expression in Patients with Huntington’s Disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1900907 – volume: 17 start-page: 1217 year: 2014 end-page: 1224 ident: 2024.06.06.597639v1.37 article-title: The GABAergic parafacial zone is a medullary slow wave sleep-promoting center publication-title: Nat Neurosci doi: 10.1038/nn.3789 – volume: 2 year: 2001 ident: 2024.06.06.597639v1.69 – volume: 389 start-page: 2203 year: 2023 end-page: 2205 ident: 2024.06.06.597639v1.6 article-title: Tominersen in Adults with Manifest Huntington’s Disease publication-title: N Engl J Med doi: 10.1056/NEJMc2300400 – volume: 40 start-page: 1500 year: 2022 end-page: 1508 ident: 2024.06.06.597639v1.11 article-title: Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates publication-title: Nat Biotechnol doi: 10.1038/s41587-022-01334-x – volume: 23 start-page: 628 year: 2017 end-page: 638 ident: 2024.06.06.597639v1.51 article-title: Unraveling Mg(2+)-RNA binding with atomistic molecular dynamics publication-title: Rna doi: 10.1261/rna.060079.116 – volume: 31 start-page: 182 year: 2023 end-page: 196 ident: 2024.06.06.597639v1.15 article-title: Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2022.12.010 – volume: 31 start-page: 1661 year: 2023 end-page: 1674 ident: 2024.06.06.597639v1.61 article-title: Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease publication-title: Mol Ther doi: 10.1016/j.ymthe.2023.05.006 – volume: 47 start-page: 10865 year: 2019 end-page: 10880 ident: 2024.06.06.597639v1.63 article-title: Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkz771 – volume: 12 start-page: 1555 year: 2003 end-page: 1567 ident: 2024.06.06.597639v1.67 article-title: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease publication-title: Hum Mol Genet doi: 10.1093/hmg/ddg169 – volume: 48 start-page: 5235 year: 2020 end-page: 5253 ident: 2024.06.06.597639v1.62 article-title: Phosphorothioate modified oligonucleotide-protein interactions publication-title: Nucleic Acids Res doi: 10.1093/nar/gkaa299 – year: 2021 ident: 2024.06.06.597639v1.19 article-title: Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System publication-title: bioRxiv doi: 10.1101/2021.02.14.431096 – volume: 37 start-page: 17105 year: 1998 end-page: 17111 ident: 2024.06.06.597639v1.23 article-title: Divalent cations stabilize unstacked conformations of DNA and RNA by interacting with base pi systems publication-title: Biochemistry doi: 10.1021/bi982201 – volume: 46 start-page: 2204 year: 2018 end-page: 2217 ident: 2024.06.06.597639v1.50 article-title: Acute hepatotoxicity of 2’ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins publication-title: Nucleic Acids Res doi: 10.1093/nar/gky060 – volume: 50 start-page: 259 year: 2010 end-page: 293 ident: 2024.06.06.597639v1.9 article-title: RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.010909.105654 – volume: 43 start-page: 189 year: 1993 end-page: 192 ident: 2024.06.06.597639v1.33 article-title: Efficacy of tribromoethanol anesthesia in mice publication-title: Lab Anim Sci – volume: 273 start-page: 1020 year: 1997 end-page: 1031 ident: 2024.06.06.597639v1.24 article-title: Affinities and selectivities of divalent cation binding sites within an RNA tertiary structure publication-title: J Mol Biol doi: 10.1006/jmbi.1997.1383 – year: 2023 ident: 2024.06.06.597639v1.34 article-title: Extended Nucleic Acid (exNA): A Novel publication-title: Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in vivo. bioRxiv doi: 10.1101/2023.05.26.542506 – volume: 35 start-page: 238 year: 2017 end-page: 248 ident: 2024.06.06.597639v1.52 article-title: The chemical evolution of oligonucleotide therapies of clinical utility publication-title: Nat Biotechnol doi: 10.1038/nbt.3765 – volume: 110 start-page: 1173 year: 2022 end-page: 1192 ident: 2024.06.06.597639v1.68 article-title: Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice publication-title: Neuron doi: 10.1016/j.neuron.2022.01.006 – volume: 8 start-page: 383 year: 2017 end-page: 394 ident: 2024.06.06.597639v1.47 article-title: Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs publication-title: Mol Ther Nucleic Acids doi: 10.1016/j.omtn.2017.07.003 – volume: 33 start-page: 234 year: 2023 end-page: 237 ident: 2024.06.06.597639v1.4 article-title: From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis publication-title: Nucleic Acid Ther doi: 10.1089/nat.2023.0027 – volume: 367 start-page: 1428 year: 2020 end-page: 1429 ident: 2024.06.06.597639v1.32 article-title: Antisense oligonucleotides for neurodegeneration publication-title: Science doi: 10.1126/science.aba4624 – volume: 22 start-page: 83 year: 2023 end-page: 88 ident: 2024.06.06.597639v1.7 article-title: 2022 FDA approvals publication-title: Nat Rev Drug Discov doi: 10.1038/d41573-023-00001-3 – volume: 117 start-page: 1116 year: 2019 end-page: 1124 ident: 2024.06.06.597639v1.21 article-title: Quantitative Studies of an RNA Duplex Electrostatics by Ion Counting publication-title: Biophys J doi: 10.1016/j.bpj.2019.08.007 – volume: 38 start-page: 5168 year: 2018 end-page: 5181 ident: 2024.06.06.597639v1.36 article-title: Genetic Activation, Inactivation, and Deletion Reveal a Limited And Nuanced Role for Somatostatin-Containing Basal Forebrain Neurons in Behavioral State Control publication-title: J Neurosci doi: 10.1523/jneurosci.2955-17.2018 – volume: 31 start-page: 589 year: 2003 end-page: 595 ident: 2024.06.06.597639v1.45 article-title: Tolerance for mutations and chemical modifications in a siRNA publication-title: Nucleic Acids Res doi: 10.1093/nar/gkg147 – volume: 43 start-page: 415 year: 2018 end-page: 425 ident: 2024.06.06.597639v1.38 article-title: Activation of the GABAergic Parafacial Zone Maintains Sleep and Counteracts the Wake-Promoting Action of the Psychostimulants Armodafinil and Caffeine publication-title: Neuropsychopharmacology doi: 10.1038/npp.2017.152 – volume: 1 start-page: 15005 year: 2015 ident: 2024.06.06.597639v1.29 article-title: Huntington disease publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2015.5 – volume: 37 start-page: 884 year: 2019 end-page: 894 ident: 2024.06.06.597639v1.12 article-title: A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system publication-title: Nat Biotechnol doi: 10.1038/s41587-019-0205-0 – volume: 12 start-page: 169 year: 2023 end-page: 185 ident: 2024.06.06.597639v1.17 article-title: Huntington’s Disease Clinical Trials Corner: August 2023 publication-title: J Huntingtons Dis doi: 10.3233/jhd-239001 – volume: 20 start-page: 427 year: 2021 end-page: 453 ident: 2024.06.06.597639v1.66 article-title: Antisense technology: an overview and prospectus publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-021-00162-z – volume: 377 start-page: 1723 year: 2017 end-page: 1732 ident: 2024.06.06.597639v1.3 article-title: Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy publication-title: N Engl J Med doi: 10.1056/NEJMoa1702752 – volume: 4 start-page: 33 year: 1983 end-page: 46 ident: 2024.06.06.597639v1.60 article-title: A survey of readily available chelators for buffering calcium ion concentrations in physiological solutions publication-title: Cell Calcium doi: 10.1016/0143-4160(83)90047-7 – volume: 24 start-page: 374 year: 2014 end-page: 387 ident: 2024.06.06.597639v1.44 article-title: Phosphorothioates, essential components of therapeutic oligonucleotides publication-title: Nucleic Acid Ther doi: 10.1089/nat.2014.0506 – volume: 387 start-page: 1099 year: 2022 end-page: 1110 ident: 2024.06.06.597639v1.5 article-title: Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS publication-title: N Engl J Med doi: 10.1056/NEJMoa2204705 – volume: 27 start-page: 297 year: 1955 end-page: 303 ident: 2024.06.06.597639v1.42 article-title: A study of calcium and magnesium in the cerebrospinal fluid publication-title: Yale J Biol Med – volume: 137 start-page: 218 year: 1957 end-page: 244 ident: 2024.06.06.597639v1.56 article-title: The action of calcium on the electrical properties of squid axons publication-title: J Physiol doi: 10.1113/jphysiol.1957.sp005808 – volume: 83 start-page: 813 year: 2014 end-page: 841 ident: 2024.06.06.597639v1.20 article-title: Understanding nucleic acid-ion interactions publication-title: Annu Rev Biochem doi: 10.1146/annurev-biochem-060409-092720 – volume: 23 start-page: 341 year: 2024 end-page: 364 ident: 2024.06.06.597639v1.55 article-title: RNAi-based drug design: considerations and future directions publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-024-00912-9 – volume: 10 start-page: 335 year: 2004 end-page: 343 ident: 2024.06.06.597639v1.22 article-title: A guide to ions and RNA structure publication-title: Rna doi: 10.1261/rna.5205404 – volume: 89 start-page: 910 year: 2016 end-page: 926 ident: 2024.06.06.597639v1.30 article-title: The Biology of Huntingtin publication-title: Neuron doi: 10.1016/j.neuron.2016.02.003 – year: 2008 ident: 2024.06.06.597639v1.70 – volume: 13 start-page: 755 year: 2019 ident: 2024.06.06.597639v1.40 article-title: Differential Role of Pontomedullary Glutamatergic Neuronal Populations in Sleep-Wake Control publication-title: Front Neurosci doi: 10.3389/fnins.2019.00755 – volume: 31 start-page: 126 year: 2021 end-page: 144 ident: 2024.06.06.597639v1.65 article-title: Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective publication-title: Nucleic Acid Ther doi: 10.1089/nat.2020.0923 – volume: 26 start-page: 1520 year: 2018 end-page: 1528 ident: 2024.06.06.597639v1.25 article-title: Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles publication-title: Mol Ther doi: 10.1016/j.ymthe.2018.03.019 – volume: 24 start-page: 2553 year: 2018 end-page: 2560.e2555 ident: 2024.06.06.597639v1.43 article-title: Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin publication-title: Cell Rep doi: 10.1016/j.celrep.2018.07.106 – volume: 7 year: 2015 ident: 2024.06.06.597639v1.59 article-title: Hypocalcemia-induced seizure: demystifying the calcium paradox publication-title: ASN Neuro doi: 10.1177/1759091415578050 – volume: 29 start-page: 1455 year: 2014 end-page: 1461 ident: 2024.06.06.597639v1.31 article-title: Huntingtin-lowering strategies in Huntington’s disease: antisense oligonucleotides, small RNAs, and gene editing publication-title: Mov Disord doi: 10.1002/mds.26020 – volume: 9 year: 2020 ident: 2024.06.06.597639v1.8 article-title: Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development publication-title: J Clin Med doi: 10.3390/jcm9062004 |
SSID | ssj0002961374 |
Score | 1.8752766 |
SecondaryResourceType | preprint |
Snippet | Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs... |
SourceID | biorxiv proquest |
SourceType | Open Access Repository Aggregation Database |
SubjectTerms | Neuroscience |
Title | Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation |
URI | https://www.proquest.com/docview/3070802920 https://www.biorxiv.org/content/10.1101/2024.06.06.597639 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La8MwDDZby2C3PdmzeLDbSHGap68rLWXQUrYVegt-KCUwktKmo_v3k5J0FLbDbiHICUi29NmSPzH2CIg5CEk7Itbg-L4ER0aedLTuGaWtjkHT3eHxJBzN_Jd5MN9r9UVllTorVtvss8rjU8E2et96cQuX9up-RbgZdhEKY3g9ZG2cUj6tyeG8-3O80pMYpyK_yWP-ORIRb_OnX364Ci7DE9aeqiWsTtkB5GfsqO4O-XXOtjt6pXzBldmUwCvyybLYZgaxMy9S3p-88b0bVLz4yBZFThTFRZlZWHM6ZiUJTnVDZINqlOo9cZVbPl7gQ5ZXAgRem1ZeF2w2HLz3R07TKMHRbhhIBwj2GNnTGKsjAZAGVqeup2XqeQZcE1nXCE1EU0ILsIhgPGkjpRBtgFUodMlaeZHDFeMiFOiKTaoQKWDwDqSPG8gIzeYG1rg6vGYPjdKSZU2HkZBiE6qOC5NasSizU2eCk5UyECqHYrNOyMHEghpk3fzjO7fsmN5VhVnxHWuVqw3cIwQodYe1nweT6WunMvo30mOu_w |
linkProvider | Cold Spring Harbor Laboratory Press |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS8NAEF7EInrziW9X0JOkbN7dg6dqqY8WQYXe4j4mJSCJtKnWP-VvdCZNRdCDF2-BbEIyuzPz7ezMN4ydAGIOQtKOaGlwgkCCI2NfOlp7RmmrW6CpdrjXj7qPwfUgHCywj3ktDKVV6qwYTbPX6hyfErbR-s6UW7i0Vw8qws2oiVAY3WuTwtR1UuUNvL_hlm18fnWB83vqeZ3Lh3bXqbsKONqNQukAYQQjPY2OLRYAaWh16vpapr5vwDWxdY3QxMoktACL7t6XNlYKXTNYlVIAFE1-g4jVSIs6g-ZXTMeT6BzjoD48_fVzEWbXv_fD-FcerbPKGnfqBUZrbAHydbY0a0n5vsGmc06nfMiVmZTAK8bLsphmBgE7L1Le7t_zb2VbvHjOhkVOvMhFmVkYc4rt0ghOyUo08dVTyjvjKre8N8SLLK8GEGKu-4dtssd_keMWW8yLHLYZF5FA-29ShfAEEUMoA9y1xrhW3NAaV0c77LgWWvIy4-BISLAJpeRFyUywOGYuzgQ1hI49VA7FZJyQVWsJ6sq1-4f3HLHl7kPvNrm96t_ssRW6X2WGtfbZYjmawAFikFIfVhPP2dN_r7RPKr7s-g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1JS8NAFB5EUby54u4IepKUyd45eLIW1yKo0Fuc5aUEJCltqu3f8hf6XpqKoAcvvQUyCcmbmfd981bGTgE5BzFpRzQ1OEEgwZGxLx2tPaO01U3QlDv80ImuX4LbbthdYJ-zXBgKq9RZMRhn75UfnwK2UftON7dw6aweVAU3owZSYYTXBpmpG32b1oGVdzD5wGPb8OKmhXN85nntq-fLa6fuLOBoNwqlA8QTjPQ0glssANLQ6tT1tUx934BrYusaoakyk9ACLEK-L22sFMIzWJWSERTV_hKu5YDaRbS7jW-7jicRIOOgdqD--clItetf_AUAFaq119jSo-rDYJ0tQL7BlqdtKSebbDyr65T3uDKjEnhV9bIsxplB0s6LlF92nviP1C1evGW9IqfayEWZWRhysu_SCE4BSzT51VPKO-cqt_yhhxdZXg0g1lz3ENtiL3OR4zZbzIscdhgXkUAMMKlCioKsIZQBnlxjXC9uaI2ro112Ugst6U_rcCQk2ITC8qJkKlgcMxNngruEXB8qh2I0TEizNQV15tr7x3uO2cpjq53c33Tu9tkq3a6Cw5oHbLEcjOAQaUipj6p55-x13gvtC68N7gI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preventing+acute+neurotoxicity+of+CNS+therapeutic+oligonucleotides+with+the+addition+of+Ca2%2B+and+Mg2%2B+in+the+formulation&rft.jtitle=bioRxiv&rft.au=Miller%2C+Rachael&rft.au=Paquette%2C+Joseph&rft.au=Barker%2C+Alexandra&rft.au=Sapp%2C+Ellen&rft.date=2024-06-08&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2024.06.06.597639&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon |